title: Neuroendocrine regulation and obesity.
abstract: The combined syndrome of android (upper body) obesity, diabetes, hyperlipidaemia and hypertension is discussed in terms of a deranged endocrine regulation of metabolism. The syndrome is characterized by insulin insensitivity and an increased control of metabolism by cortisol. The antagonism between the two hormones appears to be partly responsible for the hyperglycaemia, hypertriglyceridaemia and hypercholesterolaemia. The synergism between insulin and cortisol in stimulating energy deposition, associated with a decreased effect of corticotropin-releasing factor in stimulating energy expenditure, is likely to contribute to the development of obesity. The efficacy of D-fenfluramine in treating the obese-diabetic-hyperlipidaemic-hypertensive syndrome probably depends on its actions on the serotoninergic system in the hypothalamus which both decreases food consumption and tends to normalize hormonal balance through the hypothalamic-pituitary-adrenal axis.
authors.affiliation: Department of Biochemistry, Heritage Medical Research Centre, University of Alberta, Edmonton, Canada.
authors.forename: D N
authors.initials: DN
authors.lastname: Brindley
mesh_terms: D000818:Animals; D048909:Diabetes Complications; D004702:Endocrine Glands / Q000503:physiopathology*; D005277:Fenfluramine / Q000494:pharmacology / Q000627:therapeutic use; D006801:Humans; D006854:Hydrocortisone / Q000502:physiology; D006949:Hyperlipidemias / Q000150:complications; D006973:Hypertension / Q000150:complications; D007328:Insulin / Q000502:physiology; D009420:Nervous System / Q000503:physiopathology*; D009765:Obesity / Q000150:complications / Q000188:drug therapy / Q000503:physiopathology*; D013577:Syndrome
chemical_list: D007328:Insulin; D005277:Fenfluramine; D006854:Hydrocortisone